Background Patients with ovarian cancer usually present to a family physician with
nonspecific symptoms, most often abdominal pain. The outcome depends above all on the …

Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …

Malignant ascites is a common manifestation of advanced cancers, and treatment options
are limited. The trifunctional antibody catumaxomab (anti‐epithelial cell‐adhesion molecule …

Background Systematic pelvic and paraaortic lymphadenectomy has been widely used in
the surgical treatment of patients with advanced ovarian cancer, although supporting …

Background The role of cytoreductive surgery in relapsed ovarian cancer is not clearly
defined. Therefore, patient selection remains arbitrary and depends on the center's …

Purpose: The DESKTOP I trial proposed a score for the prediction of complete cytoreduction
in recurrent ovarian cancer. Resectability was assumed if 3 factors were present:(1) …

BACKGROUND: Borderline ovarian tumours (BOTs) are recognised as a unique entity of
ovarian tumours that do not exert infiltrative destructive growth or stromal invasion …

Purpose: Malignant ascites in ovarian carcinoma patients is associated with poor prognosis
and reduced quality of life. The trifunctional antibody catumaxomab (anti-EpCAM× anti-CD3) …

BACKGROUND.: No residual tumor as result of primary surgery in advanced ovarian cancer
is known as one of the most important prognostic factors. PURPOSE.: To evaluate the impact …

Background Identification of families at risk for ovarian cancer offers the opportunity to
consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of …